Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Poly-L-lactic acid.

Caroline M Perry1

  • 1Adis International Inc. Yardley, Pennsylvania 19067, USA. demail@adis.com

American Journal of Clinical Dermatology
|November 24, 2004
PubMed
Summary
This summary is machine-generated.

Poly-L-lactic acid injections effectively restore facial tissue in HIV patients with lipoatrophy. Studies show significant increases in skin thickness and improvements in patient-reported outcomes over 96 weeks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

Defining the Potential for Disease Modification in Atopic Dermatitis.

American journal of clinical dermatology·2026
Same journal

Atopic Dermatitis: New Targets and Emerging Systemic Therapies.

American journal of clinical dermatology·2026
Same journal

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

American journal of clinical dermatology·2026
Same journal

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same journal

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026
Same journal

What's New in Photoprotection?

American journal of clinical dermatology·2026
See all related articles

Area of Science:

  • Dermatology
  • Biomaterials Science
  • Infectious Diseases

Background:

  • Facial lipoatrophy is a common concern for patients with HIV infection.
  • Poly-L-lactic acid (PLLA) is a biodegradable polymer used for cosmetic restoration.

Purpose of the Study:

  • To evaluate the efficacy and safety of injectable PLLA for correcting facial lipoatrophy in HIV-infected individuals.
  • To assess the long-term effects of PLLA on cutaneous and dermal thickness.

Main Methods:

  • A 96-week noncomparative study involving intradermal PLLA injections in HIV patients with severe facial lipoatrophy.
  • A randomized, nonblind study comparing immediate versus deferred PLLA treatment.
  • Measurements included total cutaneous and dermal thickness, patient-reported outcomes, and photographic assessments.

Related Experiment Videos

Main Results:

  • Significant increases in cutaneous and dermal thickness were observed at multiple time points up to 96 weeks (p < 0.001).
  • 41% of patients achieved >10 mm total cutaneous thickness at the nasogenian fold by week 24.
  • Improvements in depression, anxiety, and visual analog scale assessments were noted.

Conclusions:

  • Injectable PLLA is an effective and well-tolerated treatment for facial lipoatrophy in HIV-infected patients.
  • PLLA demonstrates sustained efficacy in restoring facial volume and improving patient-reported outcomes.
  • No serious adverse events were reported, indicating a favorable safety profile.